Medications affecting the biochemical conversion to type 2 diabetes: A systematic review and meta-analysis

The Journal of Clinical Endocrinology and Metabolism
Juan Pablo DomecqMohammad H Murad

Abstract

The extent to which some pharmacological interventions reduce or increase the risk of biochemical conversion to T2DM in at-risk individuals is unclear. We searched MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews and Scopus through August 24, 2017, for randomized controlled trials evaluating the effect of drugs suspected to modify the risk of biochemical conversion to T2DM. We included 43 trials with 192,156 subjects (mean age 60 years; 56% men; mean BMI 30.4 kg/m2). Alpha-glucosidase inhibitors, angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, metformin, orlistat, phentermine-topiramate and pioglitazone significantly reduced the risk of biochemical conversion to T2DM, whereas statins and nateglinide increased the risk. There was insufficient direct evidence regarding the effects of sulfonylureas, glucagon-like peptide-1 receptor agonists, dipeptidyl peptidase-4 inhibitors and sodium-glucose cotransporter-2 inhibitors. Most trials were brief and evaluated this outcome during treatment without a withdrawal or washout period. Several drugs modify the risk of biochemical conversation to T2DM, although whether this effect is persistent and clinically...Continue Reading

References

Sep 1, 1986·Controlled Clinical Trials·R DerSimonian, N Laird
Jul 3, 1999·Diabetic Medicine : a Journal of the British Diabetic Association·C L LiH Y Wang
Oct 27, 1999·JAMA : the Journal of the American Medical Association·M FriedbergC L Bennett
Sep 1, 2000·Lancet·B DjulbegovicG H Lyman
Oct 26, 2001·JAMA : the Journal of the American Medical Association·S YusufUNKNOWN HOPE Study Investigators
Feb 8, 2002·The New England Journal of Medicine·William C KnowlerUNKNOWN Diabetes Prevention Program Research Group
Jun 28, 2002·Lancet·Jean-Louis ChiassonUNKNOWN STOP-NIDDM Trail Research Group
Nov 30, 2002·Lancet·James ShepherdUNKNOWN PROSPER study group. PROspective Study of Pravastatin in the Elderly at Risk
Dec 20, 2002·JAMA : the Journal of the American Medical Association·UNKNOWN ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatm
Mar 29, 2003·Diabetes Care·UNKNOWN Diabetes Prevention Program Research Group
Sep 6, 2003·BMJ : British Medical Journal·Julian P T HigginsDouglas G Altman
Sep 11, 2003·Diabetes Research and Clinical Practice·Chang-Yu PanHua Cheng
Sep 19, 2003·Lancet·K M Fox, UNKNOWN EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators
Jul 14, 2004·Archives of Internal Medicine·Timothy J WiltAnne Sales
Nov 9, 2004·The New England Journal of Medicine·Eugene BraunwaldUNKNOWN PEACE Trial Investigators
Nov 25, 2004·Metabolism: Clinical and Experimental·Steven R SmithGeorge A Bray
Jun 29, 2005·Circulation·Salim YusufUNKNOWN Candesartan in Heart Failure-Assessment of Reduction in Mortality and Morbidity Program Investigators
Sep 19, 2006·The New England Journal of Medicine·UNKNOWN DREAM Trial InvestigatorsRury R Holman
Mar 1, 2007·Diabetes Care·David M NathanUNKNOWN American Diabetes Association
Nov 7, 2007·The New England Journal of Medicine·John KjekshusUNKNOWN CORONA Group
Dec 12, 2007·Circulation·Jean L RouleauUNKNOWN IMAGINE (Ischemia Management with Accupril post-bypass Graft via Inhibition of the coNverting Enzyme) Investigators
Jun 5, 2008·JAMA : the Journal of the American Medical Association·Gunjan Y GandhiVictor M Montori
Aug 30, 2008·The New England Journal of Medicine·Salim YusufUNKNOWN PRoFESS Study Group
Nov 11, 2008·The New England Journal of Medicine·Paul M RidkerUNKNOWN JUPITER Study Group
Jul 22, 2009·PLoS Medicine·David MoherUNKNOWN PRISMA Group
Mar 17, 2010·The New England Journal of Medicine·Rury R HolmanRobert M Califf

❮ Previous
Next ❯

Citations

Aug 1, 2019·The Journal of Clinical Endocrinology and Metabolism·James L RosenzweigBruno L Vergès
Mar 5, 2020·Antioxidants & Redox Signaling·Karen Bernard, Victor J Thannickal
Apr 25, 2020·Evidence-based Complementary and Alternative Medicine : ECAM·Jing KeDong Zhao

❮ Previous
Next ❯

Related Concepts

Related Feeds

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.